CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

Announcement

You can now add alternative names! Click here to add other names that you've published under.

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.

Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996 Oct 15; 88(8):3223-9.

View in: PubMed

subject areas

Adult
Antigens, CD34
Blood Transfusion
Bone Marrow Transplantation
Cell Count
Child
Cohort Studies
Female
Flow Cytometry
Graft Survival
Hematologic Neoplasms
Hematopoietic Stem Cells
Humans
Life Tables
Lymphocyte Depletion
Male
Middle Aged
Prognosis
Survival Analysis
Time Factors
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome

authors with profiles

Michele Fox